Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Lee's Pharmaceutical Holdings Limited (0950.HK)
Hong Kong, HK
Lee's Pharmaceutical Holdings Limited, an investment holding company, develops, manufactures, markets, and sells pharmaceutical products in the People's Republic of China, Hong Kong, and internationally. It focuses on various disease areas, such as cardiovascular, woman's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. It operates in Proprietary and Generic Products; and Licensed-In Products segments. The Proprietary and Generic Products segment manufactures and sells Nadroparin Calcium injection and Livaracine to treat blood clots and deep vein thrombosis; Yallaferon for viral infection; Slounase for hemostasis; Socazolimab Injection for Recurrent or metastatic cervical cancer; Treprostinil injection for pulmonary arterial hypertension; fondaparinux sodium injection for deep vein thrombosis; and Sodium Phenylbutyrate Granules to treat urea cycle disorders; Apremilast Tablets for Plaque psoriasis; and Azilsartan Tablets for hypertension. The Licensed-In Products segment offers Sancuso for chemotherapy induced nausea and vomiting; Bredinin to treat Immunosuppression in renal transplantation; Centraxal Plus for acute otitis media with tympanostomy tubes; and Ferplex to treat iron deficiency anemia. This segment also offers Intrarosa for vulvovaginal atrophy; Adasuve for agitation associated with schizophrenia or bipolar I disorder in adults; Mictonorm for urinary incontinence; Natulan for Stage III and IV Hodgkin's disease; Lutrate for Prostate cancer; Nitric Oxide for Inhalation for Hypoxic respiratory failure associated with pulmonary hypertension; Omacor to treat Omega-3-acid ethyl esters; Zanidip for hypertension; Readyfusor for post-operative pain management; Teglutik to treat Amyotrophic lateral sclerosis; Trittico for insomnia/depression; Dicoflor and VSL#3 for probiotics; and Zingo for topical local analgesics. The company was founded in 1994 and is headquartered in Sha Tin, Hong Kong.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.91% | -1.85% | -5.36% | -25.87% | -37.65% | -30.26% | -28.38% | -25.35% | -77.87% | -83.17% | +103.85% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Pharmaceuticals: +7.8%+2.6% Q4'25: -0.1% (vs Q4'24)
-
EPS growth Medical - Pharmaceuticals: +20.2%+0.0% Q4'25: -19.2% (vs Q4'24)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%+9.3% ★ Q4'25: +25.5% (vs Q4'24)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+7.7% ★ Q4'25: +5.9% (vs Q4'24)
-
ROIC Medical - Pharmaceuticals: +6.1%+4.1% Q4'25: +2.8% (vs Q4'24)
-
Share dilution Medical - Pharmaceuticals: +0.0%+0.0% Q4'25: +0.1% (vs Q4'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×1.57× ★ Q4'25: 2.61× (vs Q4'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
922.15M
est: 1.09B (-15.3%)
|
929.82M
est: 958.12M (-3.0%)
|
1.01B
est: 1.02B (-0.7%)
|
1.14B
est: 1.15B (-1.3%)
|
1.22B
est: 1.21B (+0.4%)
|
1.22B
est: 1.21B (+0.2%)
|
1.27B
est: 1.30B (-2.4%)
|
1.23B
est: 1.36B (-9.1%)
|
1.05B
est: 1.04B (+1.5%)
|
1.40B
est: 1.28B (+9.6%)
|
1.44B
est: 1.46B (-1.7%)
|
| EBITDA |
301.05M
est: 388.50M (-22.5%)
|
332.14M
est: 342.07M (-2.9%)
|
319.99M
est: 362.44M (-11.7%)
|
516.17M
est: 411.49M (+25.4%)
|
235.55M
est: 433.44M (-45.7%)
|
279.43M
est: 433.36M (-35.5%)
|
2.13B
est: 462.93M (+359.1%)
|
229.06M
est: 484.41M (-52.7%)
|
193.05M
est: 370.29M (-47.9%)
|
260.87M
est: 432.78M (-39.7%)
|
198.04M
est: 494.86M (-60.0%)
|
| EBIT |
256.54M
est: 284.92M (-10.0%)
|
286.41M
est: 250.86M (+14.2%)
|
261.88M
est: 265.80M (-1.5%)
|
451.09M
est: 301.77M (+49.5%)
|
128.65M
est: 317.87M (-59.5%)
|
151.92M
est: 317.82M (-52.2%)
|
1.97B
est: 339.50M (+481.4%)
|
76.56M
est: 355.25M (-78.4%)
|
43.55M
est: 271.56M (-84.0%)
|
111.94M
est: 322.30M (-65.3%)
|
110.28M
est: 368.54M (-70.1%)
|
| Net Income |
229.05M
est: 240.40M (-4.7%)
|
252.00M
est: 259.09M (-2.7%)
|
232.56M
est: 263.74M (-11.8%)
|
418.27M
est: 246.51M (+69.7%)
|
63.35M
est: 100.10M (-36.7%)
|
129.32M
est: 217.87M (-40.6%)
|
1.99B
est: 117.77M (+1,587.4%)
|
51.28M
est: 97.16M (-47.2%)
|
16.70M
est: 76.15M (-78.1%)
|
93.10M
est: 84.98M (+9.6%)
|
91.94M
est: 83.24M (+10.5%)
|
| SGA |
368.78M
est: 497.68M (-25.9%)
|
350.74M
est: 438.20M (-20.0%)
|
373.37M
est: 464.30M (-19.6%)
|
410.67M
est: 527.13M (-22.1%)
|
490.85M
est: 555.25M (-11.6%)
|
517.67M
est: 555.15M (-6.8%)
|
663.70M
est: 593.02M (+11.9%)
|
544.88M
est: 620.55M (-12.2%)
|
494.19M
est: 474.36M (+4.2%)
|
596.29M
est: 574.86M (+3.7%)
|
557.12M
est: 657.33M (-15.2%)
|
| EPS |
0.40
est: 0.41 (-2.0%)
|
0.43
est: 0.44 (-2.3%)
|
0.39
est: 0.45 (-12.9%)
|
0.71
est: 0.42 (+69.6%)
|
0.11
est: 0.17 (-35.3%)
|
0.22
est: 0.37 (-40.5%)
|
3.38
est: 0.20 (+1,590.0%)
|
0.09
est: 0.17 (-47.2%)
|
0.03
est: 0.13 (-78.0%)
|
0.16
est: 0.14 (+10.9%)
|
0.16
est: 0.14 (+13.2%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-28 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-27 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-26 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-22 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-21 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-20 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 3/5 | 3/5 | 5/5 |
| 2026-05-19 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-18 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-15 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-14 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-13 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-12 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-11 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 3/5 | 5/5 |
| 2026-05-08 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 4/5 | 5/5 |
| 2026-05-07 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 4/5 | 5/5 |
| 2026-05-06 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 4/5 | 5/5 |
| 2026-05-05 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 4/5 | 5/5 |
| 2026-05-04 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-30 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-29 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-28 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-27 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-24 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 4/5 | 5/5 |
| 2026-04-23 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-22 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-21 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-20 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-17 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-16 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 3/5 | 5/5 |
| 2026-04-15 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 3/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 64.0K | 0.39% |
| 2 | Avantis Emerging Markets Equity ETF AVEM | 0.00% | 93.0K | 0.33% |
| 3 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 32.8K | 0.28% |
| 4 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 276.73 | 0.44% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Wanee Leelalertsuphakun | MD, Chief Marketing & Sales Officer and Executive Director | 17M | female |
| Siu Fong Lee | Chairman & Compliance Officer | 16M | female |
| Xiaoyi Li | Founder, Senior Adviser & Non-Executive Director | 8M | — |
| Yuanjue Sun | Chief Medical Officer | — | male |
| Yueshen Chen | Director of Administration in China | — | male |
| Ling Fang | Corporate Culture and Public Relations Director | — | female |
| Zhongyu Jiao | Group Deputy GM & GM of the Risk Control Centre | — | male |
| Tsui Victor Kailok | Group Chief Manufacturing Officer | — | male |
| Yiu Ming Chow | Group Chief Financial Officer & Company Secretary | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 0950.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
